The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ICML 2023 | Brentuximab vedotin-nivolumab alone and then with R-CHP as frontline therapy for PMBCL
Raphael Steiner, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses a trial investigating brentuximab vedotin plus nivolumab alone and then in combination with rituximab-cyclophosphamide-doxorubicin-prednisone (R-CHP) as frontline therapy for patients with primary mediastinal large B-cell lymphoma (PMBCL; NCT04745949). Dr Steiner describes the structure of the regimen, and shares data regarding the efficacy and safety of the treatment so far. Dr Steiner notes the occurrence of immune-related adverse events (AEs), which were managed with the use of dexamethasone. This interview took place at the 17th International Conference on Malignant Lymphoma (ICML), held in Lugano, Switzerland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Research funding: Seagen, BMS, GSK, Rafael Pharmaceuticals
